|

Mortality and Cardiovascular Diseases in Adult-onset Type 1 Diabetes

RECRUITINGSponsored by Karolinska Institutet
Actively Recruiting
SponsorKarolinska Institutet
Started2024-01-01
Est. completion2025-05-31
Eligibility
Age18 Years – 110 Years
Healthy vol.Accepted

Summary

Scarce evidence is available for prognosis in adult-onset type 1 diabetes (T1D). The aim of this study is to investigate the risk of all-cause mortality, cause-specific mortality, and incident CVD in adult-onset T1D, as compared to type 2 diabetes with comparable age at diagnosis and population controls. We will explore potential modifiable factors including lifestyle and clinical characteristics that contribute to T1D prognosis. In addition, we will estimate the life expectancy associated with different age at T1D diagnosis as compared to population controls. This study will be based on people with diabetes recorded in Swedish National Diabetes Registers, with linkages to other nationwide registers to retrieve data on lifestyle factors, biomarkers, treatment and outcome information.

Eligibility

Age: 18 Years – 110 YearsHealthy volunteers accepted
Inclusion Criteria:

* people with adult-onset (≥18 years) T1D diagnosed in 2001-2020 from the National Diabetes Register
* all T2D cases diagnosed at age ≥18 years in 2001-2020 recorded in the National Diabetes Register

Everyone with T1D was matched by age, sex, and county to 50 population controls from the Total Population Register.

Exclusion Criteria:

* To avoid diabetes secondary to pancreatic cancer, we excluded people diagnosed with cancer in the digestive system 1 year prior to diabetes diagnosis and with pancreatic cancer as the underlying cause of death.

Conditions3

DiabetesType 1 DiabetesType 2 Diabetes

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.